ALLR vs. PRFX, ATNF, QLGN, INM, PXMD, CMND, NBSE, BPTH, GLMD, and LSDI
Should you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include PainReform (PRFX), 180 Life Sciences (ATNF), Qualigen Therapeutics (QLGN), InMed Pharmaceuticals (INM), PaxMedica (PXMD), Clearmind Medicine (CMND), NeuBase Therapeutics (NBSE), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), and Lucy Scientific Discovery (LSDI). These companies are all part of the "pharmaceutical preparations" industry.
Allarity Therapeutics (NASDAQ:ALLR) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
PainReform received 1 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave PainReform an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.
11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 0.0% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Allarity Therapeutics had 2 more articles in the media than PainReform. MarketBeat recorded 5 mentions for Allarity Therapeutics and 3 mentions for PainReform. PainReform's average media sentiment score of 0.96 beat Allarity Therapeutics' score of 0.68 indicating that PainReform is being referred to more favorably in the news media.
Allarity Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Summary
PainReform beats Allarity Therapeutics on 8 of the 9 factors compared between the two stocks.
Get Allarity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allarity Therapeutics Competitors List
Related Companies and Tools
